Skip to main content

Table 2 Baseline PT-INR values and ratios of PT-INR to the baseline PT- INR at designated daptomycin concentrations

From: Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification

Reagent Plasma group Baseline PT-INR (mean ± SD) PT-INR50/PT-INR0 a PT-INR100/PT-INR0 a PT-INR150/PT-INR0 a
1: HemosIL RecombiPlasTin 2G A (INR 1) 0.96 ± 0.00 1.01 1.03 1.04
B (warfarin, INR 2) 1.70 ± 0.01 1.04 1.09 1.14
C (warfarin, INR 3) 2.57 ± 0.01 1.07 1.11 1.17
D (LC, INR 2) 1.63 ± 0.02 1.02 1.07 1.11
2: Neoplastin Plus A (INR 1) 0.97 ± 0.02 1.03 1.05 1.09
B (warfarin, INR 2) 1.82 ± 0.01 1.03 1.05 1.06
C (warfarin, INR 3) 2.75 ± 0.02 1.06 1.07 1.11
D (LC, INR 2) 1.83 ± 0.00 1.02 1.07 1.11
3: STA Neoplastin R A (INR 1) 0.99 ± 0.02 1.03 1.09 1.09
B (warfarin, INR 2) 1.88 ± 0.02 1.09 1.12 1.19
C (warfarin, INR 3) 2.86 ± 0.02 1.09 1.13 1.18
D (LC, INR 2) 1.54 ± 0.01 1.07 1.14 1.22
  1. PT prothrombin time, INR international normalized ratio, SD standard deviation, LC liver cirrhosis
  2. a PT-INR0 represents the baseline PT-INR. PT-INR50, PT-INR100, and PT-INR150 represent the PT-INR at daptomycin concentrations of 50, 100, and 150 μg/mL, respectively. The relative change in PT-INR was calculated using the mean values of PT-INR measured in triplicate at each daptomycin concentration